February 6 (SeeNews) - Serbian drug maker Hemofarm said it has assumed responsibility for the markets of Poland, the Czech Republic and Slovakia of its German parent Stada, becoming its hub for Central and Eastern Europe (CEE).
Hemofarm has additionally increased the area of its regional competence, which has so far comprised the markets in Southeast Europe, the Serbian company said in a statement on Monday.
"The new role granted to Hemofarm is a remarkable recognition of Stada for the work and the results we achieved in the previous period. This is also good news for Serbia and the entire region, particularly bearing in mind that it is rarely seen that a company operating in a non-EU member country is entrusted with managing also the markets within the EU," the CEO of Hemofarm and vice president of Stada, Ronald Seeliger, said in the statement.
Seeliger added that their plans are ever more ambitious with the new markets.
Hemofarm's investments will be focused on the expansion of capacities, further upgrading of product quality, research and development of medicinal products, and particularly on the workforce of around 3000 diligent, high-quality, educated people, Seeliger said.
The Serbian company became part of the large international Cinven and Bain Capital family through Stada in 2017 and its products are available in 38 countries on three continents.
Hemofarm’s factories are located in Serbia, Montenegro and Bosnia and Herzegovina. The company has also assumed the role of the promoter of sustainable development and responsible operation in the region, Hemofarm said.